Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02064543
Other study ID # STU 072012-090
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2013
Est. completion date January 2017

Study information

Verified date September 2019
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The project is a prospective trial comparing Zeno/GAITRite and APDM® in a cohort of persons living with parkinsonian disorders. Ambulatory patients with a parkinsonian syndrome and who are able to provide informed consent will participate in the assessments.

Outcome variables include selected gait and balance parameters such as cadence, gait-cycle, stride-length, stride-velocity, turning duration, turning steps, postural sway and anticipatory postural control. These parameters will be measured by the portable inertial sensors developed by APDM® and the Zeno/GaitRite.


Description:

Testing

Participants after screening and consenting will:

1. Have their height measured and fit with the APDM Opals (each device is a two inch square attached by velcro), one device is attached to each leg, each arm, and the trunk and chest and receive an introduction to walking on the gait mat.

2. Participants are then asked to walk at a self selected walking speed down the gait mat. The participants will complete multiple passes (8-10 passes, total 75-100 feet) across the gait mat while wearing the APDM units to concurrently collect all temporal and spatial data needed to answer the research question. The Zeno mat is the intended primary gait mat for this study. The GaitRite will only be utilized in the case of a technical issue with the Zeno in order to insure completion of the data collection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria

1. Adults between the ages of 18 and 80 years of age with a primary diagnosis of PD and similar parkinsonian syndromes

2. Individuals able to walk 100 feet independently, with or without the use of an assistive device (walker, cane) and follow simple instructions.

3. Individuals with sufficient physiological systemic support to participate in the study protocol

Exclusion Criteria

1. Inability to speak English secondary to the need to understand and follow multistep directions

2. A secondary diagnosis (musculoskeletal, cardiopulmonary, neurological) that excludes participation in the study

3. Inability to ambulate 100 feet independently with or without an assistive device.

4. Inability to follow simple instructions necessary for completion of the testing tasks.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
GAITRite
mobility test assessing gait parameters
ADPM
mobility test assessing gait parameters

Locations

Country Name City State
United States UT Southwestern Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary gait parameters Outcome variables include selected gait and balance such as cadence one year
Primary gait parameters Outcome variables include selected gait and balance such as stride-length one year
Primary gait parameters Outcome variables include selected gait and balance such as stride-velocity one year
Primary gait parameters Outcome variables include selected gait and balance such as turning duration one year
Primary gait parameters Outcome variables include selected gait and balance such as turning steps one year
Primary gait parameters Outcome variables include selected gait and balance such as postural sway one year
Primary gait parameters Outcome variables include selected gait and balance such as anticipatory postural control one year
See also
  Status Clinical Trial Phase
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Active, not recruiting NCT05127057 - Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT) N/A
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT03314610 - Effect of Need to Void on Parkinsonian Gait
Recruiting NCT05506891 - Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy Phase 2
Completed NCT00950196 - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Phase 4
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Enrolling by invitation NCT05514106 - MIBG in Aging and Neurologic Disorders Phase 4
Completed NCT01581645 - Mobilaser Study to Help With People Who Are Having Problems With Their Gait Phase 0
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Completed NCT02214862 - 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Phase 0
Recruiting NCT04518059 - Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Withdrawn NCT01329926 - Molecular Analysis of Human Neural Stem Cells
Terminated NCT00745030 - Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism N/A
Completed NCT04222218 - Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy N/A
Completed NCT03386669 - Novel Neuroimage Study in Tauopathies With Parkinsonism Phase 2
Active, not recruiting NCT05308485 - Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease